Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hydro Fill Technology is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, AULAKH, CHARANJIT. The portfolio is limited to 1 distinct art unit, suggesting that the company's biological innovations are focused on a specific technical niche. This concentration allows the company to develop a deep understanding of the examination practices within that particular unit.
AULAKH, CHARANJIT serves as the busiest examiner for this portfolio, with 1 busiest examiner pending action. This figure represents the total number of active matters the company has at the patent office. With 1 distinct examiner overseeing the entire pending workload, the company can maintain a singular prosecution narrative. This reduces the risk of conflicting arguments that can arise when dealing with multiple examiners.
The presence of 1 pending office action indicates a low volume of active prosecution. Because only 1 distinct art unit is involved, the legal team can specialize in the technical standards and precedents relevant to that group. Practitioners can expect a direct relationship with AULAKH, CHARANJIT during this phase. This streamlined profile is typical for companies with a very focused intellectual property strategy in the biotech field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289789 | COMPOSITIONS AND USE THEREOF FOR RE-ESTABLISHING INTESTINAL PERMEABILITY AND/OR PREVENTING OR COMBATTING MULTIFACTORIAL DISEASES | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289789 | COMPOSITIONS AND USE THEREOF FOR RE-ESTABLISHING INTESTINAL PERMEABILITY AND/OR PREVENTING OR COMBATTING MULTIFACTORIAL DISEASES | AULAKH, CHARANJIT | 1621 | §112 | Non-Final OA | — | Pending | Jul 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHydro Fill Technology has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of Hydro Fill Technology's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
